

To whom it may concern:

Company Name : TOHO HOLDINGS CO., LTD.  
Representative : Norio Hamada /  
President and Representative Director  
(Securities Code: 8129 / First Section of Tokyo Stock Exchange)  
Contact: Katsuya Kato  
Corporate Officer and General Manager of  
Corporate Communications Office  
and Corporate Planning Office  
(TEL: 03-5259-9520)

Notice regarding the Establishment of a New Company, “Orphan Trust Japan Co., Ltd.”, Aimed at  
Providing a Comprehensive Solution to Specialty Pharmaceuticals Distribution Problems

TOHO HOLDINGS CO., LTD. (Head Office: Setagaya-ku, Tokyo; Representative Director and President; Norio Hamada, hereinafter “TOHO HOLDINGS”) has set up a wholly-owned subsidiary, Orphan Trust Japan Co., Ltd. (hereinafter “Orphan Trust Japan”), to deal with various distribution problems of the specialty pharmaceuticals market.

1. Intent and Purpose of Establishing the New Company

New pharmaceuticals targeting specialty and niche areas expected to be launched one after the other from this point onward are forecast to form a new market, albeit smaller in size than the traditional market for new drugs, focusing on more specialized fields such as cancers and rare diseases with a view to satisfying unmet medical needs, i.e. addressing the lack of effective drugs.

Furthermore, many of these specialty pharmaceuticals will be handled in a way unique and specific to them and they will be handled in a difficult manner in the treatment of difficult diseases. Accordingly, pharmaceutical wholesalers are required to play a new role and serve a new function in their distribution so that we can realize and maximize the value of each product.

In the context of the expected change in the market environment as mentioned above, TOHO HOLDINGS has newly established the “Orphan Trust Japan Co., Ltd.” with the aim of comprehensively supporting customers and solving an array of distribution problems of the specialty pharmaceuticals market in Japan. The Orphan Trust Japan will: draw on TOHO HOLDING’s knowhow on the partially exclusive sales of specialty pharmaceuticals cultivated thus far through the pharmaceutical wholesaling business; realize quality control covering all temperature zones backed by TOHO HOLDING’s knowledge and technologies of temperature control systems nurtured through the reagents and other businesses; provide a stable supply based on lean channel inventory to customers throughout Japan underpinned by the swift and efficient distribution network utilizing the Kyoso Mirai Group network; ensure traceability from the pharmaceutical company all the way through to the patients making full use of IT technologies; and be equipped with new functions such as those of providing information to medical care providers such as doctors and pharmacists as well as patients and gathering information capitalizing on internal resources (including marketing specialists and call centers).

The Company hopes that the business model of the Orphan Trust Japan will permeate and take root in the Japanese market and help each of the unmet medical needs to be satisfied and thus be resolved, thereby achieving the Group’s corporate slogan of “Total Commitment to Good Health” in a concrete manner and creating a healthier and more dynamic society.

## 2. Outline of the Company

- |                              |  |
|------------------------------|--|
| (1) Company name             | Orphan Trust Japan Co., Ltd.   |
| (2) Corporate representative | Shinichi Kurakata President  |
| (3) Principal place          | 2-5-23 Kanda Surugadai, Chiyoda-ku, Tokyo  |
| (4) Business contents        | [1] Distribution management and sales of prescription pharmaceuticals, investigational new drugs, etc., based on high-quality, swift and efficient traceability<br>[2] Provide appropriate information on pharmaceuticals to medical care providers as well as patients and collect information<br>[3] Studies and research on specialty pharmaceuticals distribution in international markets<br>[4] Provide pharmaceutical companies, medical institutions, medical care providers and patients with solutions to specialty pharmaceuticals-related issues |
| (5) Establishment            | April 1, 2013  |
| (6) Capital                  | 50 million yen   |
| (7) Employees                | 10   |
| (8) Major shareholders       | TOHO HOLDINGS CO., LTD. 100.0%   |